Apptomics aims to establish its digital platform as the standard for monitoring movement disorders

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/monkeybusinessimages)
(Image: Getty/monkeybusinessimages)

Related tags: BBK, Digital biomarker, Parkinson’s disease, Clinical trials

Apptomics is working with BBK and Biotaware to develop the remote health-monitoring platform, which recently served as a digital biomarker to evaluate treatment effects as part of an essential tremor clinical trial.

Apptomics announced Monday that its digital platform E.V.A (Evaluation. Validation. Action) has been used successfully in a study for essential tremor. Researchers used the platform as an “exploratory digital biomarker”​ in addition to standard clinical scales to evaluate treatment effects.

Georgia Mitsi, PhD, MBA, Co-founder and CEO, Apptomics, told us app is being used in a sub study to look at the use of objective criteria and its role in evaluating movement disorders. 

Apptomics, which provides digital health solutions, partnered with the patient recruitment and engagement technology firm BBK Worldwide in 2016 to develop a suite of mobile apps for patients, caregivers, physicians, and payers. The company also is working with Biotaware to develop the platform, which it hopes will become the standard for monitoring movement disorders.

“BBK is an investor and has been commissioned to advance the user interface and assist in the evolution in the application,”​ Joan F. Bachenheimer, founding principal and CEO, BBK Worldwide, told us. BBK is working with Biotaware also to ensure the data integrity and the evaluation of the metrics, she said.

The E.V.A platform – originally dubbed iMotor – has been updated to include the addition of a digital spirography, a functional test of upper limb function. It also can be paired with electronic clinical outcome assessment (eCOA) and electronic data capture (EDC) platforms, according to the company.

Currently, E.V.A is being evaluated for its ability to help assess patient response to investigational treatments in a Phase III study in essential tremor as well as several Phase II studies in Parkinson’s disease and essential tremor.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more